Alivus Life Sciences Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

3 Soumi Rao, Tushar Mistry, Yasir Rawjee

Analysts

6 Ahmed Madha, Bhawana Israni, Kaustav, Pratik Kothari, Sucrit D. Patil, Yog Rajani

Financials & KPIs

Geographic & Segment Commentary

• Non-GPL Business: Delivered 26.5% YoY growth, driven by new product launches gaining scale across markets. Management noted launch momentum is strong because patent expiries are staggered across markets, allowing sequential entry into new geographies. Product mix and operational efficiencies improved gross margins by 510 bps YoY; management expects launch-driven margin stability to persist with second-generation process improvements ready.

• GPL Business: Declined 52.6% YoY on inventory rationalization by a large, long-standing customer (50+ commercial products supplied). Q1 is not considered indicative of the year; management guided to flattish FY27 growth with a traditional H2-weighted pattern, providing confidence in the ₹700-750 crore annualized range.

• CDMO Business: Grew 3.8% YoY; inherently lumpy. Two new contracts expected to close in early H2 FY27 are on track, with active discussions on ~7 new projects. Management expects CDMO to outpace overall company growth in the medium term, supported by lifecycle management and specialty projects (including 505(b)(2) filings). Margin profile is accretive but overall volume remains small relative to API.

• HP API Portfolio: 29 products in active pipeline representing $82 billion TAM; 13 products validated, 7 in advanced development, 9 in lab development. Patent expiry-driven commercial ramp is expected to begin end of calendar 2027 (FY28), with launch quantities possibly slightly earlier in API.

Company-Specific & Strategic Commentary

• Solapur Ramp & Regulatory Milestone: Solapur Phase 1/1.1 to be operational early Q3 FY27 (slower-than-guided due to labor slowdown); management targets a major regulatory agency inspection within a year of commissioning to service regulated markets (initially ROW business only, plus captive large-volume intermediates and backward integration block). Ankleshwar and Dahej brownfield expansions on track and on time (Dahej +160 KL, Ankleshwar +110 KL), providing capacity comfort through FY28 without rushing Solapur Phase 2.

• Solvent Recovery & Cost Competitiveness: Introduced membrane-based solvent recovery technology supplementing distillation; expected 5-10% improvement in recovery. Net solvent consumption is favorable for Alivus processes, but wider product basket requires a bigger solvent range, making raw material costs (solvents, PSMs) an active monitoring focus amid geopolitical tensions.

• M&A Strategy - "API Plus": Actively evaluating synergistic opportunities targeting lateral expansion; explicitly ruled out acquisitions solely for capacity or conventional pipeline. Seeks one-plus-one-equals-three-or-four deals—platform technologies that extend value across both API and CDMO segments.

• R&D Investment: R&D at 3.7% of sales (₹24 crores), trending to ~4% steady state. Spend directed largely to new API development (pipeline growth) and next-generation/second-gen process development to protect margins; some CDMO analytical and regulatory support.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Gross Margin Sustainability and Guidance Conservatism

• Question: How much of the 510 bps gross margin improvement is from process improvements vs. new launches that may normalize? Is 60% sustainable? (Ahmed Madha)
• Answer: Launches will not drop off—second-gen processes are always ready, new molecules still have markets opening. Operational efficiency gains are incremental and continuing. EBITDA guidance of 30-32% is conservative; company could guide up to 34%, but the war situation and raw material prices warrant caution—"we tell you what we can do, and if there's an upside, there's an upside." (Yasir Rawjee)

GPL Business Confidence

• Question: What gives confidence to deliver flat GPL for FY27 after a 52.6% Q1 decline? (Ahmed Madha)
• Answer: GPL is a very old, very large customer with 50+ commercial products; Q1 was inventory assimilation, not a demand signal. "Worst case it will be a flattish growth." (Yasir Rawjee)

Margin Mix - GPL vs Non-GPL

• Question: Is non-GPL more margin accretive than GPL? Will EBITDA blend lower when GPL recovers in H2? (Yog Rajani; Kaustav)
• Answer: Yes, non-GPL is more margin accretive. Given Q1 at 36.6%, if GPL comes back, steady-state EBITDA margin could settle around 34%. Guidance of 30-32% factors in the GPL mix shift. (Yasir Rawjee; Tushar Mistry)

Execution Priorities & Compliance

• Question: Top 2-3 execution priorities and biggest risks (regulatory, compliance, client adoption)? (Sucrit D. Patil)
• Answer: Priority #1 is getting Solapur operational (by Diwali) and triggering a major regulatory inspection within a year to unlock a 3-4 year runway. #2 is executing launches correctly—patents expire at different times across markets, driving significant volume growth. Compliance track record is strong: FDA VAI at Ankleshwar, NAI at Dahej; this year's audit calendar is relatively light from major agencies. (Yasir Rawjee)

Financial Risk Management (Margins, Cash Flow, Receivables)

• Question: Key financial risks and specific measures for margins, cash flow, and balance sheet strength? (Sucrit D. Patil)
• Answer: Raw material prices rising (solvents to PSMs); monitoring almost daily, engaging customers more regularly to pass on costs. No receivable defaults; exchange rate favorably benefiting net exporter status. Building inventory at favorable prices to support customers predictably, leading to slight inventory increase. Balance sheet remains robust with ₹880 crores cash, debt-free. (Tushar Mistry)

Volume/Price Split and Solapur Delay

• Question: Can you break down growth into volume and price? Why Solapur pushed out again? (Pratik Kothari)
• Answer: Non-GPL FX impact ~7%; constant currency ~20% growth, of which volume +21-22%, price -1 to -2%. Solapur deliberately not hurried—Phase 2 would cause under-absorption. Ankleshwar and Dahej brownfield expansions on schedule; capacity comfortable for FY27-FY28. Once Solapur is inspected, business can be driven hard from it. (Tushar Mistry; Yasir Rawjee)

Capacity Sufficiency for Double-Digit Growth

• Question: Is existing capacity (Ankleshwar, Dahej, Solapur pre-inspection) enough for double-digit growth in FY27-FY28? (Ahmed Madha)
• Answer: Yes. Solapur will not run empty—mapped products including large-volume intermediates for captive consumption and a big backward integration block will keep it busy from start. Initially ROW business only for ~a year. (Yasir Rawjee)

R&D Spend and PAT Margins

• Question: Will rising R&D (3.7% of sales) pressure PAT margins? What areas is spend going to? (Yog Rajani)
• Answer: Steady state R&D ~4% of sales. Spend largely new API development (pipeline growing nicely), second-generation process work to protect margins, and some CDMO analytical/regulatory support. PAT margins will continue to be good—pipeline drives both growth and margins. (Yasir Rawjee)

Acquisition Strategy

• Question: With ₹800+ crores on balance sheet, are you interested in FDA-approved facilities or companies with pipelines? (Yog Rajani)
• Answer: Not spending on facilities—capacity is not a growth constraint, facilities are top of the line. Pipeline only if it comes from a very different platform. Actively seeking synergistic one-plus-one-equals-three-or-four opportunities, "API Plus" lateral expansion across API and CDMO. (Yasir Rawjee)

CDMO Growth Trajectory

• Question: How many new CDMO customers added, what's the inquiry flow, and how will CDMO pan out over next 2-3 years? (Bhawana Israni)
• Answer: Active discussions on ~7 new projects; current revenue from 5 projects. Indian CDMO companies are in a sweet spot, especially from the U.S. Focus on lifecycle management and specialty (505(b)(2)); projects can scale in 1-1.5 years with fast regulatory approvals. CDMO expected to grow faster than overall business, with margin improvement split between CDMO and new API launches. (Yasir Rawjee)

Key Takeaway

Alivus Life Sciences delivered Q1 FY27 revenue of ₹640 crores (+6.4% YoY), with non-GPL growth of 26.5% fully offsetting a 52.6% collapse in the GPL business due to customer inventory rationalization. Gross margin expanded 510 bps to 60.2% and EBITDA margin 650 bps to 36.6%, driven by new launches, product mix, and operational efficiency—including a new membrane-based solvent recovery technology. Management maintained FY27 guidance of 10-12% revenue growth (H2-skewed) and 30-32% EBITDA margins, acknowledging potential upside to 34% if the war-driven raw material environment stabilizes. Strategic focus centers on commissioning Solapur in early Q3 FY27 with a regulatory inspection targeted within a year, on-track Ankleshwar/Dahej brownfield expansions, a 617-filing DMF/CEP pipeline, and 29 HP API products targeting an $82 billion TAM. CDMO momentum builds with two H2 contracts on track and seven active project discussions. Watch items include GPL recovery in H2, raw material inflation pass-through, and Solapur regulatory milestones that gate FY29 growth capacity.